According to a post on the FDA’s website, Regeneron’s cemdisiran was granted orphan designation in treatment of Myasthenia Gravis.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on REGN:
- Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023
- REGN, CTLT Continue Sliding Following FDA Rejection of Eylea Drug
- Catalent confirms being Regeneron’s Eylea 8 mg third party filler, says Stephens
- Catalent says FDA made three observations in Eylea inspection, Bloomberg reports
- Uber downgraded, Pinterest upgraded: Wall Street’s top analyst calls